DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Effect of Antecedent Hypoglycaemia on β2-Adrenergic Sensitivity

Information source: Radboud University
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Diabetes; Hypoglycemia Unawareness

Intervention: Hypoglycemia (Procedure)

Phase: N/A

Status: Active, not recruiting

Sponsored by: Radboud University

Official(s) and/or principal investigator(s):
Paul Smits, PhD, MD, Principal Investigator, Affiliation: Radboud University

Summary

Hypoglycaemia unawareness is a common complication in patients with type 1 diabetes and with insulin-treated type 2 diabetes of long duration. The loss of autonomic symptoms to hypoglycemia does not solely depend on loss of adrenaline responses. Differences in sensitivity to catecholamines may also be involved.

Reconciling the data on β2-adrenergic receptor polymorphism to those on loss of β-adrenergic sensitivity in diabetic patients with hypoglycemia unawareness, we hypothesize that hypoglycemia unawareness is at least partly the result of desensitization of the β2-adrenergic receptor and that patients who are homozygous for arginine at codon 16 are particularly susceptible for this desensitization process, whereas patients who are homozygous for glycine at codon 16 are resistant for desensitization.

Objectives

1. To determine whether, and if so to what extent, antecedent hypoglycemia reduces β2-adrenergic sensitivity in healthy subjects with Arg16 homozygosity.

2. To investigate whether or not healthy subjects with Gly16 homozygosity are resistant to desensitization

3. To confirm that antecedent hypoglycemia reduces the heart rate response to isoproterenol and to assess to what extent this reduced response is mediated by impairments in baroreflex sensitivity.

Clinical Details

Official title: The Effect of Antecedent Hypoglycaemia on β2-Adrenergic Sensitivity in Subjects With Homozygous Arg16 and gly16 Polymorphism of the β2-Adrenergic Receptor

Study design: Diagnostic, Randomized, Single Blind, Placebo Control, Crossover Assignment

Eligibility

Minimum age: 18 Years. Maximum age: 40 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Informed consent

- Homozygous for Arginine at codon 16 or homozygous Gly at codon 16

- No regular usage of medication other than oral contraceptives

Exclusion Criteria:

- History of cerebrovascular, cardiovascular, or peripheral vascular disease

- Smoking

- Alcohol usage of more than 10 units per week

- Inability to abstain from xanthine-derivatives (coffee, tea, cola, chocolate, cacao)

or alcohol for 2 days

- BMI above 30 kg/m2

- Participation to any other trial in the preceding 3 months

- Ongoing disease of any kind

- Pregnancy

Locations and Contacts

Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland 6500HB, Netherlands
Additional Information

Starting date: April 2005
Ending date: February 2007
Last updated: February 28, 2007

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012